$575 Million

bluebird bio, Inc

Follow-on Offering

Bookrunner, May 2020

bluebird bio, Inc

bluebird bio, Inc. is a biotechnology company focused on researching, developing, and commercializing gene therapies for severe genetic diseases and cancer. The Company’s programs in severe genetic diseases include ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) gene therapy for the treatment of transfusion-dependent β-thalassemia (TDT), LentiGlobin® for the treatment of sickle cell disease (SCD) and Lenti-D™ for the treatment of cerebral adrenoleukodystrophy (CALD). The Company’s oncology programs are focused on developing novel T cell-based immunotherapies, including CAR and TCR T cell therapies. Idecabtagene vicleucel (ide-cel, bb2121) and bb21217 are CAR-T cell product candidates for the treatment of multiple myeloma (MM) and both are in collaboration with Bristol-Myers Squibb (BMS).